Our findings not only enrich the mechanism of PD‐L1 regulation in NSCLC and identify KLF12 as a novel transcription factor for PD‐L1 but also provide a basis for targeting KLF12 for NSCLC immunotherapy. Here, KLF12 is linked to non-small cell lung carcinoma.